About immunome inc - IMNM
Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.
IMNM At a Glance
Immunome, Inc.
18702 North Creek Parkway
Bothell, Washington 98011
| Phone | 1-425-939-7410 | Revenue | 6.94M | |
| Industry | Biotechnology | Net Income | -212,394,000.00 | |
| Sector | Health Technology | Employees | 177 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
IMNM Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 270.321 |
| Price to Book Ratio | 3.831 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -5.809 |
| Enterprise Value to Sales | 176.728 |
| Total Debt to Enterprise Value | 0.003 |
IMNM Efficiency
| Revenue/Employee | 39,214.689 |
| Income Per Employee | -1,199,966.102 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.015 |
IMNM Liquidity
| Current Ratio | 14.687 |
| Quick Ratio | 14.687 |
| Cash Ratio | 14.525 |
IMNM Profitability
| Gross Margin | 57.427 |
| Operating Margin | -3,084.757 |
| Pretax Margin | -3,059.991 |
| Net Margin | -3,059.991 |
| Return on Assets | -46.001 |
| Return on Equity | -52.089 |
| Return on Total Capital | -33.28 |
| Return on Invested Capital | -51.544 |
IMNM Capital Structure
| Total Debt to Total Equity | 0.608 |
| Total Debt to Total Capital | 0.604 |
| Total Debt to Total Assets | 0.564 |
| Long-Term Debt to Equity | 0.608 |
| Long-Term Debt to Total Capital | 0.604 |